These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8892744)

  • 21. Effect of eicosapentaenoic acid in patients with refractory myelodysplastic syndrome.
    Okamoto T; Okada M; Wakae T; Takatsuka H; Kakishita E
    Am J Hematol; 2002 Dec; 71(4):350-1. PubMed ID: 12447972
    [No Abstract]   [Full Text] [Related]  

  • 22. Haem arginate as a treatment for myelodysplastic syndromes.
    Ruutu T; Volin L; Tenhunen R
    Br J Haematol; 1987 Apr; 65(4):425-8. PubMed ID: 3580298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.
    Spiriti MA; Latagliata R; Niscola P; Cortelezzi A; Francesconi M; Ferrari D; Volpe E; Clavio M; Grossi A; Reyes MT; Musto P; Mitra ME; Azzarà A; Pagnini D; D'Arena G; Spadano A; Balleari E; Pecorari P; Capochiani E; De Biasi E; Perego D; Monarca B; Pisani F; Scaramella G; Petti MC
    Ann Hematol; 2005 Mar; 84(3):167-76. PubMed ID: 15592833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myelodysplastic syndromes: more prevalent than we know.
    Sandhu SK; Sekeres MA
    Geriatrics; 2008 Nov; 63(11):10-7. PubMed ID: 18998762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [RS3PE syndrome: an acute edematous polyarthritis of the elderly with variable prognosis].
    Beyne-Rauzy O; Revel V; Desfossez V; Bousquet E; Nourhashemi F; Adoue D
    Ann Med Interne (Paris); 2001 Jun; 152(4):276-8. PubMed ID: 11474377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
    Giagounidis AA; Haase S; Germing U; Schlegelberger B; Wilkens L; Büsche G; Kreipe HH; Wysk J; Grips KH; Grabenhorst U; Rothmann F; Lübbert M; Ganser A; Aivado M; Heinsch M; Aul C
    Ann Hematol; 2005 Jun; 84(6):389-94. PubMed ID: 15785949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anticytosine therapy for primary myelodysplastic syndrome].
    Abdulkadyrov KM; Gritsaev SV; Bessmel'tsev SS; Martynkevich IS; Tiranova SA; Blinov MN; Osipova RI
    Vopr Onkol; 2003; 49(4):464-6. PubMed ID: 14569938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A study of erythropoietin use for myelodysplastic syndrome].
    Márquez Saavedra E; Artacho Criado S
    Farm Hosp; 2004; 28(6):395-401. PubMed ID: 15628941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [An elderly patient with myelodysplastic syndrome successfully treated with combination of granulocyte-colony stimulating factor and continuous-drip infusion of low-dose cytarabine and etoposide].
    Yamada T; Tsurumi H; Hara T; Fukuno K; Goto H; Oyama M; Moriwaki H
    Rinsho Ketsueki; 2000 Mar; 41(3):218-21. PubMed ID: 10774251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome.
    Ferrero D; Campa E; Dellacasa C; Campana S; Foli C; Boccadoro M
    Haematologica; 2004 May; 89(5):619-20. PubMed ID: 15136232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue.
    Caocci G; Baccoli R; Ledda A; Littera R; La Nasa G
    Leuk Res; 2007 Feb; 31(2):249-52. PubMed ID: 16814382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome.
    Koeffler HP; Aslanian N; O'Kelly J
    Leuk Res; 2005 Nov; 29(11):1259-62. PubMed ID: 16164982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [ Myelodysplastic syndrome].
    Fenaux P
    Rev Prat; 2002 Dec; 52(20):2301-8. PubMed ID: 12621953
    [No Abstract]   [Full Text] [Related]  

  • 36. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.
    Moreno-Aspitia A; Colon-Otero G; Hoering A; Tefferi A; Niedringhaus RD; Vukov A; Li CY; Menke DM; Geyer SM; Alberts SR;
    Cancer; 2006 Aug; 107(4):767-72. PubMed ID: 16826578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes.
    Latagliata R; Oliva EN; Volpicelli P; Carmosino I; Breccia M; Vincelli I; Alati C; Napoleone L; Vozella F; Nobile F; Alimena G
    Acta Haematol; 2008; 120(2):104-7. PubMed ID: 18974634
    [No Abstract]   [Full Text] [Related]  

  • 39. Trisomy 14 in myelodysplastic syndromes: report of two cases and review of the literature.
    Vasef MA; Murata-Collins JL; Alsabeh R; Medeiros LJ
    Arch Pathol Lab Med; 1998 Jan; 122(1):77-83. PubMed ID: 9448022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic myelomonocytic leukemia with overlap dysplastic/proliferative presentation.
    Gologan R; Stoia R; Radulescu I; Georgescu D; Ostroveanu D
    Leuk Res; 2007 Jun; 31(6):878-9. PubMed ID: 16956659
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.